SSRI Whistleblower Claims

October 31, 2013

Important Information

ClassAction.org is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects
Employees in the pharmaceutical industry with information supporting theories that companies are knowingly marketing selective serotonin reuptake inhibitors to treat all levels of depression even though they are aware that the drugs are only effective in patients with severe depression.
Damages
These individuals may be able to file a whistleblower lawsuit on behalf of the government and collect 15% to 25% of the recovered damages.
Company(ies)
SSRI Pharmaceutical Companies
Additional Details
SSRIs are one of the most expensive and frequently prescribed drugs in the country, and are often paid by Medicaid and Medicare, government health programs for low-income, disabled and elderly citizens. Companies that acquire government funds through fraudulent activity may be held liable through a False Claims Act lawsuit, in which a whistleblower files an action on behalf of the government and stands to receive a portion of the recovery.